
anjum khan
@anjumkhan12
ID: 367662310
04-09-2011 10:29:13
418 Tweet
196 Followers
4,4K Following


Fantastic paper by the HOVON-SAKK AML group in @BloodJournal corroborating equally poor outcomes in TP53mut AML & HR-MDS. We need to define a new sub-classification of TP53mut MDS/AML w/ clinical trials evaluating novel Txās for both HR-MDS & AML. ashpublications.org/blood/article/ā¦

Moving the needle for MPN-related inflammation with Dr Fleischman - do kimchi & kefir hold the answer? @leedshaem ā¦European Hematology Associationā© #EHA2022


Great to see the initial Magro data for TP53mut AML at EHA2022: much work remains - are triplets the answer? Looks like allografts arenāt going away anytime soon..@leedshaem European Hematology Association

NPM1 mutant AML just got a little more complexā¦Valuable real world data from Dr Hernandez-Sanchez & the HARMONY Alliance - just how much risk stratification will the average clinician tolerate? ā¦@leedshaemā© ā¦European Hematology Associationā© ā¦HARMONY Alliance Foundationā© ā¦ā¦#AML


For hemepath enthusiasts everywhere, does the route to the mysterious pseudoPelger Huet anomaly lie in the spliceosome? Great work from Dr Su & the Slush lab @leedshaem European Hematology Association #hemepath


ELN 2022 is here! All change for AML as unveiled by Prof Dohner - FLT3 allelic ratio & MDS-excess blasts are out, in comes MDS/AML - makes a lot of sense for patients, a little more work for the bio-informaticiansā¦#AMLsm #EHA2022 European Hematology Association @leedshaem


The new ELN2022 AML risk classification is here ! A welcome simplification away from allelic ratio, MRD moves to the fore for NPM1. Strong argument for timely NGS reporting & upfront tissue typing if transplant-eligible #AMLsm #EHA2022 European Hematology Association @leedshaem AML Hub


The case for re-branding ānot-so benignā/non-malignant haem as Classical Haematology - a smart idea for a huge field ā¦Sickle Cell Societyā© ā¦@leedshaemā© ā¦European Hematology Associationā© thelancet.com/journals/lanhaā¦


EHA2022 ends with a bang! Immunotherapy in B-cell disease, a call to action on increasing access to new therapies for the majority of sickle patients, & the IPSS-M finally lands with improved risk stratification for half of MDS patients. #MDS #EHA2022 @leedshaem European Hematology Association








Sorry to keep banging on about this, Rishi Sunak, but we do think you're on to something here. Perhaps we could all get access and maybe we could repair all the damage Brexit has done. Just a though. Let us know what you think! Sincerely, the UK.

